Fuji Pharma Signs License Agreement for Darbepoetin Alfa, An erythropoiesis-stimulating agents

Tokyo-Japan, January 5, 2016 - Fuji Pharma Co., Ltd. (TSE: 4554) today announced that the company has signed a license agreement with Chong Kun Dang Pharmaceutical Corp. (Head office: Seoul, South Korea; President: Kim Young Joo). Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribute and sell of Darbepoetin Alfa Biosimilar.

Darbepoetin Alfa is an erythropoiesis-stimulating agent (ESA) with long acting effects. It is effective for improving renal anemia of non-dialysis chronic kidney disease and hemodialysis patients which widely used in Japanese market.

Darbepoetin Alfa Biosimilar is Fuji Pharma’s second biosimilar product following Filgrastim BS injection Syringe (F), a recombinant human granulocyte colony-stimulating factor (G-CSF) drug which have been marketed in 2013.

Fuji Pharma started a five-year business plan in the fiscal year that ended in September 2019. Under the theme of “Fuji Pharma Branding.” aiming to establish a unique business model that produces synergies in strategic fields by combining brands, generic drugs and contract manufacturing.

Chong Kun Dang is one of the leading pharmaceutical companies in Korea operating globally based on strong pipelines of biopharmaceuticals and other drugs with outstanding R&D capabilities.

Fuji Pharma is aiming to increase the Brand Strength in acute medical care area, which is one of Fuji Pharma’s strategic fields. As a company mission, Fuji Pharma plans to contribute individuals who have chronic renal failure by providing new treatment options.

About Chong Kun Dang Pharmaceutical
Established: May 1941
Head office: Seoul, South Korea
CEO: Kim Young Joo
Capital: 23,523 million Korean Won
Sales: 544,130 million Korean Won (2014)
Business: Primarily pharmaceutical R&D, manufacturing and sales; also active drug ingredients, health food and other activities at group companies

About Fuji Pharma Co., Ltd.
Established: April 1965
Head office: Tokyo, Japan
CEO: Hirofumi Imai, President & CEO
Capital: ¥3,799 million
Stock Listings Tokyo Stock Exchange, First Section (TSE: 4554)
Business: Medical care for women, in vitro diagnostics, acute medical care products and curative medicine (injection agents), and information regarding pharmaceuticals and health

To read more Press Release articles, click here.